Stock News

Analysts See $-0.70 EPS for Omeros Corporation (OMER)

Omeros Corporation (NASDAQ:OMER) LogoInvestors sentiment increased to 1.38 in Q2 2018. Its up 0.34, from 1.04 in 2018Q1. It improved, as 13 investors sold Omeros Corporation shares while 21 reduced holdings. 20 funds opened positions while 27 raised stakes. 21.45 million shares or 5.18% more from 20.39 million shares in 2018Q1 were reported.
Blackrock stated it has 0% in Omeros Corporation (NASDAQ:OMER). D E Shaw And Company owns 0.02% invested in Omeros Corporation (NASDAQ:OMER) for 906,527 shares. Amer International Group has invested 0% in Omeros Corporation (NASDAQ:OMER). Stifel Finance holds 465,411 shares or 0.03% of its portfolio. Credit Suisse Ag stated it has 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Lesa Sroufe Com holds 17,075 shares. Metropolitan Life Ins Communication stated it has 14,854 shares or 0% of all its holdings. Cypress Group has 0.09% invested in Omeros Corporation (NASDAQ:OMER). Davenport Limited Liability Corporation stated it has 54,450 shares or 0.01% of all its holdings. Voya Investment Mgmt Ltd Company stated it has 18,729 shares. Daiwa Securities Group owns 265 shares. Ingalls And Snyder Lc has 5.61M shares. Fincl Bank Of America De has invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Northern Corporation holds 618,533 shares or 0% of its portfolio. Victory Mgmt reported 1,570 shares stake.

Since May 14, 2018, it had 0 buys, and 4 sales for $2.59 million activity. 23,792 Omeros Corporation (NASDAQ:OMER) shares with value of $566,160 were sold by JACOBSEN MICHAEL A.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.70 EPS on November, 8.They anticipate $0.63 EPS change or 900.00 % from last quarter’s $-0.07 EPS. After having $-0.60 EPS previously, Omeros Corporation’s analysts see 16.67 % EPS growth. The stock increased 3.96% or $0.61 during the last trading session, reaching $16.03. About 902,211 shares traded or 8.79% up from the average. Omeros Corporation (NASDAQ:OMER) has risen 28.58% since October 24, 2017 and is uptrending. It has outperformed by 12.96% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 3 analysts covering Omeros Corp (NASDAQ:OMER), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Omeros Corp had 5 analyst reports since May 3, 2018 according to SRatingsIntel. Maxim Group maintained it with “Buy” rating and $32 target in Friday, August 10 report. Wedbush maintained the shares of OMER in report on Wednesday, May 16 with “Hold” rating. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Thursday, May 3 with “Buy” rating. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Friday, May 11 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Friday, May 25.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $778.41 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Streetinsider.com which released: “Pre-Open Movers 10/02: (DTEA) (OMER) (CLVS) Higher; (SFIX) (NBEV) (VNE) Lower (more…)” on October 02, 2018, also Businesswire.com with their article: “FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant …” published on October 23, 2018, Globenewswire.com published: “New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe’s Companies, and …” on October 23, 2018. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Streetinsider.com and their article: “Omeros (OMER) Says FDA Granted Orphan Drug Designation to its OMS721 for Treatment of HSCT-TMA” published on October 23, 2018 as well as Fool.com‘s news article titled: “Why Omeros Corporation Stock Is Bouncing Back Today” with publication date: October 02, 2018.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*